CTKB
Cytek BioSciences Inc

265
Mkt Cap
$703.26M
Volume
6.94M
52W High
$7.30
52W Low
$2.37
PE Ratio
-54.40
CTKB Fundamentals
Price
$5.87
Prev Close
$4.57
Open
$4.99
50D MA
$4.02
Beta
1.42
Avg. Volume
688,717.87
EPS (Annual)
-$0.0461
P/B
1.86
Rev/Employee
$309,341.05
Loading...
Loading...
News
all
press releases
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up - Time to Buy?
Cytek Biosciences (NASDAQ:CTKB) Shares Gap Up - Here's What Happened...
MarketBeat·2h ago
News Placeholder
More News
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Price Target Lowered to $7.50 at Piper Sandler
Piper Sandler dropped their target price on Cytek Biosciences from $8.00 to $7.50 and set an "overweight" rating on the stock in a research report on Tuesday...
MarketBeat·3d ago
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Trading Up 19.3% - Here's What Happened
Cytek Biosciences (NASDAQ:CTKB) Trading Up 19.3% - Here's What Happened...
MarketBeat·8d ago
News Placeholder
Cytek Biosciences (NASDAQ:CTKB) Announces Quarterly Earnings Results
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) issued its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of $0.01 by ($0.05). The...
MarketBeat·9d ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q3 Loss, Tops Revenue Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of -200.00% and +1.70%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·10d ago
News Placeholder
Alvotech (ALVO) Surges 8.6%: Is This an Indication of Further Gains?
Alvotech (ALVO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·2mo ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Beats Q2 Earnings Estimates
Cytek Biosciences (CTKB) delivered earnings and revenue surprises of +150.00% and -3.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates
chainwire·6mo ago
News Placeholder
Preview: Cytek Biosciences's Earnings
read more...
Benzinga·1y ago
News Placeholder
Piper Sandler Reaffirms Their Buy Rating on Cytek Biosciences (CTKB)
Piper Sandler analyst David Westenberg maintained a Buy rating on Cytek Biosciences (CTKB Research Report) today and set a price target of $8.00...
TipRanks Financial Blog·1y ago

Latest CTKB News

View

Advertisement|Remove ads.

Advertisement|Remove ads.